SCHEMBL12929613

SCHEMBL12929613

CCOC(=O)c1cnc(-c2ccccc2OC)nc1NCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 3/20 0.57
▸ RAB9A P51151 1/20 0.57
▸ LMNA P02545 4/20 0.56
▸ TSHR P16473 4/20 0.56
▸ MAPT P10636 4/20 0.56
▸ HSD17B10 Q99714 4/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ TP53 P04637 2/20 0.56
▸ ALOX15 P16050 2/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ POLB P06746 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ PPP1CA P62136 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ AGTR1 P30556 6/20 0.54
▸ AGTR2 P50052 6/20 0.54
▸ CYP1A2 P05177 4/20 0.54
▸ CYP3A4 P08684 4/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12929645 0.89 NPSR1 (0.60) NPSR1RAB9ALMNATSHRMAPT
SCHEMBL12929351 0.88 ALDH1A1 (0.64) NPSR1RAB9ALMNATSHRMAPT
SCHEMBL12929381 0.87 NPSR1 (0.58) NPSR1RAB9ALMNATSHRMAPT
SCHEMBL12929695 0.86 ALDH1A1 (0.53) NPSR1RAB9ALMNATSHRMAPT
SCHEMBL11164512 0.85 NPSR1 (0.67) NPSR1RAB9ALMNATSHRMAPT
SCHEMBL11159729 0.82 ALDH1A1 (0.66) NPSR1RAB9ALMNATSHRMAPT
SCHEMBL12929697 0.81 CDC7 (0.61) NPSR1RAB9ALMNATSHRMAPT
SCHEMBL12929526 0.80 NPSR1 (0.57) NPSR1RAB9ALMNATSHRMAPT
SCHEMBL12929397 0.80 ADORA3 (0.67) NPSR1RAB9ALMNATSHRMAPT
SCHEMBL12929336 0.79 ALDH1A1 (0.68) RAB9ALMNATSHRMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 — — US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 — — US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 — — US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS KCNJ1, KCNJ11, TRPV1 NPSR1 2654/4885RAB9A 2446/4885LMNA 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback